Great post from JRock777 over on Ihub
Well worth the read!
Is now the time to buy?
Let's take a look at some of the fundamentals behind Amarantus and some technical issues as far as trading. Today's news was huge for AMBS. Basically stating that data was strong enough preliminarily to execute an option and take the data and create an outline for a clinical trial. The current analyst, Jason Napadano, is giving very little consideration in his price reflection for MANF until they are ready to put manf into a clinical trial. Well it seems like the company is positioning to do just that. Remember that the big deal with targeting Retinitas pigmentosa is that most likely AMBS will file for an orphan indication. The filing alone will be a value inflection. If the data is good and the trial is well put together then there is no reason that we shouldn't receive fast track designation (another value inflection).
Now let's take a technical look at the stock and put the puzzle together mixed with potential short term catalyst. The market was waiting for data for the anticipated lympro sets. The anticipation pushed the stock to almost .20 a share on high volume. The data that came out was a small population and was statistically significant enough to so that there was a difference between the control and the treatment group. The market did not understand the data and there was a sell off. The overselling was actually into very promising and a great data set. Technically we are in the .10 range and on today's open we had a few hundred thousand shares traded. Out of no where sellers sold 6 million shares in a matter of minutes and the market absorbed the shares with very little downward movement. This technically shows that currently it should remain at minimum this price. Now let's mix the fundamentals with the technicals. We have a floor and know that the front line data was great and ambs is over subscribing the trial. This shows confidence in management in the front line information. Remember the market sold based on misunderstanding these findings. So why would management take a chance with the oversubscription? Well the more people in the study the more risk but also the more opportunity for a reward. AMBS has stated that they are in talks with a negotiation for a partnership. By being over subscribed this will increase the value if the numbers are what management believes they will be. Huge confidence sign. We know that the results will come out between now and the next few weeks and that ambs most likely will each a partnership almost immediately after.
Remember we are also anticipating projections for lympro along with the start of eltropozine in the phase 2b. All of which management has indicated that they are going to be gearing for an uplist to a national exchange.
Buckle up
Is now the time to buy?
Let's take a look at some of the fundamentals behind Amarantus and some technical issues as far as trading. Today's news was huge for AMBS. Basically stating that data was strong enough preliminarily to execute an option and take the data and create an outline for a clinical trial. The current analyst, Jason Napadano, is giving very little consideration in his price reflection for MANF until they are ready to put manf into a clinical trial. Well it seems like the company is positioning to do just that. Remember that the big deal with targeting Retinitas pigmentosa is that most likely AMBS will file for an orphan indication. The filing alone will be a value inflection. If the data is good and the trial is well put together then there is no reason that we shouldn't receive fast track designation (another value inflection).
Now let's take a technical look at the stock and put the puzzle together mixed with potential short term catalyst. The market was waiting for data for the anticipated lympro sets. The anticipation pushed the stock to almost .20 a share on high volume. The data that came out was a small population and was statistically significant enough to so that there was a difference between the control and the treatment group. The market did not understand the data and there was a sell off. The overselling was actually into very promising and a great data set. Technically we are in the .10 range and on today's open we had a few hundred thousand shares traded. Out of no where sellers sold 6 million shares in a matter of minutes and the market absorbed the shares with very little downward movement. This technically shows that currently it should remain at minimum this price. Now let's mix the fundamentals with the technicals. We have a floor and know that the front line data was great and ambs is over subscribing the trial. This shows confidence in management in the front line information. Remember the market sold based on misunderstanding these findings. So why would management take a chance with the oversubscription? Well the more people in the study the more risk but also the more opportunity for a reward. AMBS has stated that they are in talks with a negotiation for a partnership. By being over subscribed this will increase the value if the numbers are what management believes they will be. Huge confidence sign. We know that the results will come out between now and the next few weeks and that ambs most likely will each a partnership almost immediately after.
Remember we are also anticipating projections for lympro along with the start of eltropozine in the phase 2b. All of which management has indicated that they are going to be gearing for an uplist to a national exchange.
Buckle up
